title: Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery.
abstract: Fe(III)-carboxylate nanoscale metal-organic frameworks (NMOFs) with the MIL-101 structure were synthesized using a solvothermal technique with microwave heating. The approximately 200 nm particles were characterized using a variety of methods, including SEM, PXRD, nitrogen adsorption measurements, TGA, and EDX. By replacing a percentage of the bridging ligand (terephthalic acid) with 2-amino terephthalic acid, amine groups were incorporated into the framework to provide sites for covalent attachment of biologically relevant cargoes while still maintaining the MIL-101 structure. In proof-of-concept experiments, an optical contrast agent (a BODIPY dye) and an ethoxysuccinato-cisplatin anticancer prodrug were successfully incorporated into the Fe(III)-carboxylate NMOFs via postsynthetic modifications of the as-synthesized particles. These cargoes are released upon the degradation of the NMOF frameworks, and the rate of cargo release was controlled by coating the NMOF particles with a silica shell. Potential utility of the new NMOF-based nanodelivery vehicles for optical imaging and anticancer therapy was demonstrated in vitro using HT-29 human colon adenocarcinoma cells.
authors.affiliation: Department of Chemistry, CB#3290, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
authors.forename: Kathryn M L
authors.initials: KM
authors.lastname: Taylor-Pashow
authors.forename: Joseph
authors.initials: J
authors.lastname: Della Rocca
authors.forename: Zhigang
authors.initials: Z
authors.lastname: Xie
authors.forename: Sylvie
authors.initials: S
authors.lastname: Tran
authors.forename: Wenbin
authors.initials: W
authors.lastname: Lin
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D001896:Boron Compounds / Q000737:chemistry; D002264:Carboxylic Acids / Q000008:administration & dosage / Q000737:chemistry*; D003287:Contrast Media / Q000008:administration & dosage / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D005290:Ferric Compounds / Q000008:administration & dosage / Q000737:chemistry*; D019073:HT29 Cells; D006801:Humans; D053768:Metal Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D008958:Models, Molecular; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000737:chemistry; D010795:Phthalic Acids / Q000737:chemistry; D013386:Succinates / Q000008:administration & dosage / Q000737:chemistry; D014961:X-Ray Diffraction
chemical_list: C095489:4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; D000970:Antineoplastic Agents; D001896:Boron Compounds; D002264:Carboxylic Acids; D003287:Contrast Media; D005290:Ferric Compounds; D009944:Organoplatinum Compounds; D010795:Phthalic Acids; D013386:Succinates; C000620954:ethoxysuccinato-cisplatin; C011363:terephthalic acid